On Sep 13, 2018 European Patent Office (EPO) maintained
patent covering sofosbuvir compound in amended form after hearing in opposition
proceedings.
According to news published, Médecins Sans Frontières (MSF –
Doctors Without Borders), announced the decision, said it “is gravely
disappointed with the European Patent Office’s decision to uphold US
pharmaceutical corporation Gilead’s Sciences’ patent related to the key hepatitis
C drug sofosbuvir.” Médecins Sans Frontières (MSF) along with 3 other parties filed
post grant opposition to EP 2604620 patent in March 2017. EPO held oral
proceeding on Sep 13, 2018 & maintained patent in amended form. EP’’620 is
set to expire in Apr 2024. SPC has been filed in many countries & if
granted would expire in Mar/Apr 2029.
No comments:
Post a Comment